These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20140880)

  • 21. Supplementary analysis of probabilities at the termination of a group sequential phase II trial.
    Liu A; Wu C; Yu KF; Gehan E
    Stat Med; 2005 Apr; 24(7):1009-27. PubMed ID: 15565737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flexible design of two-stage adaptive procedures for phase III clinical trials.
    Koyama T
    Contemp Clin Trials; 2007 Jul; 28(4):500-13. PubMed ID: 17307399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bias of estimates of the number needed to treat.
    Duncan BW; Olkin I
    Stat Med; 2005 Jun; 24(12):1837-48. PubMed ID: 15806616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simple efficient bias corrected instrumental variable estimator for randomized trials with noncompliance.
    Chan KC
    Contemp Clin Trials; 2012 Jul; 33(4):786-93. PubMed ID: 22484340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bias-corrected maximum likelihood estimator of the intraclass correlation parameter for binary data.
    Saha KK; Paul SR
    Stat Med; 2005 Nov; 24(22):3497-512. PubMed ID: 16007569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The bayesian bias correction method of the first-order approximation of nonlinear mixed-effects models for population pharmacokinetics.
    Funatogawa T; Funatogawa I
    J Biopharm Stat; 2007; 17(3):381-92. PubMed ID: 17479388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian estimation of intervention effect with pre- and post-misclassified binomial data.
    Stamey JD; Seaman JW; Young DM
    J Biopharm Stat; 2007; 17(1):93-108. PubMed ID: 17219757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Data-driven analysis strategies for proportion studies in adaptive group sequential test designs.
    Wassmer G
    J Biopharm Stat; 2003 Nov; 13(4):585-603. PubMed ID: 14584710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blinded and unblinded internal pilot study designs for clinical trials with count data.
    Schneider S; Schmidli H; Friede T
    Biom J; 2013 Jul; 55(4):617-33. PubMed ID: 23703749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal spending functions for asymmetric group sequential designs.
    Anderson KM
    Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new noninferiority test for independent dichotomous variables based on a shrinkage proportion estimator.
    Almendra-Arao F
    J Biopharm Stat; 2015; 25(1):157-69. PubMed ID: 24836379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using the instrumental variables estimator to analyze noninferiority trials with noncompliance.
    Kim MY
    J Biopharm Stat; 2010 Jul; 20(4):745-58. PubMed ID: 20496203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of adaptive allocation rules for group-sequential binary response clinical trials.
    Morgan CC; Stephen Coad D
    Stat Med; 2007 Apr; 26(9):1937-54. PubMed ID: 16981177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-post-test designs with substantial dropout rates.
    Salim A; Mackinnon A; Christensen H; Griffiths K
    Psychiatry Res; 2008 Sep; 160(3):335-45. PubMed ID: 18718673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methods of estimation in log odds ratio regression models.
    Breslow NE; Cologne J
    Biometrics; 1986 Dec; 42(4):949-54. PubMed ID: 3814734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The distribution of the maximum likelihood estimator in up-and-down experiments for quantal dose-response data.
    Vågerö M; Sundberg R
    J Biopharm Stat; 1999 Aug; 9(3):499-519. PubMed ID: 10473034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-stage k-sample designs for the ordered alternative problem.
    Shan G; Hutson AD; Wilding GE
    Pharm Stat; 2012; 11(4):287-94. PubMed ID: 22408050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
    Zhang Y; Mietlowski W; Chen B; Wang Y
    J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sample size re-estimation for adaptive sequential design in clinical trials.
    Gao P; Ware JH; Mehta C
    J Biopharm Stat; 2008; 18(6):1184-96. PubMed ID: 18991116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.